Molecular and Cellular Research on Lung Cancer: A Development toward Precision Medicine
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 1467
Special Issue Editors
Interests: lung cancer; precision medicine; thoracic surgery; mini-invasive surgery; patient-derived organoids; peri operative treatment
2. Methodology and Quality of Life in Oncology Unit, University Hospital, Besançon, France
3. EFS BFC, INSERM, Université de Bourgogne Franche-Comté, UMR1098, RIGHT, Besançon, France
Interests: lung cancer; cochrane methodology of systematic reviews and meta-analyses in lung cancer; patient reported outcomes; peri operative treatment; lung cancer biomarker (screening, detection, diagnosis, prognosis, prediction, stratification, therapy response monitoring)
2. Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, MI, Italy
Interests: lung cancer; NSCLC; robotic surgery; screening program; precision medicine
Special Issue Information
Dear Colleagues,
The past decade has been transformative for lung cancer patients, physicians and scientists.
The discovery of NSCLC mutations that confers specific sensitivity to several drugs in lung cancer adenocarcinoma and the introduction of a turning point in lung cancer immunotherapy (Anti–PD-(L)1) allowed to improve the prognosis of lung cancer and to open a new frontier of a medicine adapted to each patient: precision medicine.
The fruits of precision medicine are visible every day now in lung cancer clinical practice: patients receive molecular testing to determine whether their tumor harbors an actionable mutation and drugs targeting the immune system are showing their activity in care.
However, the extraordinary promise of precision medicine is tempered by the fact that the newest treatments are effective only in a small fraction of patients and we still known little about the tumor immune microenvironment.
This special issue will focus on cellular aspects in the development of in vitro testing devices, the discovery of new biomarkers to overcome resistance to existing treatments as well as the arrival of artificial intelligence and its implications in liquid biopsies or the stratification of organized lung cancer screening.
This special issue will be organized in 3 parts:
- Lung cancer screening and perspectives: association with AI and cancer predictive biomarkers;
- Response to treatment specific biomarkers;
- Screening strategies and innovative treatment for lung cancer: organoid-based predictive platform and novel immunotherapy pathways.
Dr. Joseph Seitlinger
Dr. Guillaume Eberst
Dr. Giuseppe Mangiameli
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung cancer
- precision medicine
- immunotherapy
- targeted therapy
- organoids
- AI
- oncolytic viruses
